Skip to content

Expiratory Muscle Training and Trunk Flexion in Parkinson's Disease

Effect of Expiratory Muscle Strength Training on Forward Trunk Flexion in Parkinson's Disease

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06963918
Enrollment
30
Registered
2025-05-09
Start date
2025-08-31
Completion date
2026-01-31
Last updated
2025-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson Disease, Expiratory Muscle Strength Training, Forward Trunk Flexion

Brief summary

Postural abnormalities involving the trunk are prevalent in over 20% of patients with Parkinson's disease (PD). Pathological forward trunk flexion (FTF) is a drug-refractory complication in patients with PD leading to imbalance, pain and fall-related injuries. Deep abdominal muscle training is a key rehabilitation strategy for FTF, as muscles like the transversus abdominis and multifidus are crucial for lumbar stabilization. This training has been shown to improve body position and lumbar proprioception. Abdominal muscles are also responsible for forced expiration. Expiratory muscle strength training (EMST) utilizing forced expiration through expiratory trainer has emerged as a beneficial intervention in the non-pharmacological management of PD, positively impacting clinical aspects such as dysphagia, dystussia, hypokinetic dysarthria, and drooling. EMG study showed large abdominal muscles activity, particularly the transversus abdominis and internus obliquus abdominis during EMST. Therefore, EMST might also be effective in improving lumbar stabilization. Given the established role of abdominal muscles in trunk stabilization, it is plausible that activation of deep abdominal muscles during EMST with the right level of resistance might improve FTF in PD patients. No studies have yet examined the effect of EMST on posture in PD. The primary aim of this study will be to evaluate the effect of EMST on forward trunk flexion in patients with Parkinson's disease. The secondary aim will be to assess the potential duration of the EMST effect on postural abnormalities and its impact on patient stability.

Interventions

After the 4-week wait-to-start period during which they will not receive any intervention, will participants undergo a 4-week respiratory training program using the EMST150™ device (Expiratory Muscle Strength Trainer). EMST therapy sessions will be completed at home on 5 days (of the patients choosing) per week, performing five sets of five forceful exhalations through the EMST150™. The resistance of the device will be set to 75% of the patient's individual maximum expiratory pressure (MEP). The daily training will take approximately 15 minutes. Following the training period, patients will be observed for an additional 4 weeks to assess the sustainability of the potential training effects.

Sponsors

General University Hospital, Prague
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Parkinson's Disease * Age ≥ 18 years * MoCA (Montreal Cognitive Assessment) score ≥19 * Pathological forward trunk flexion defined as thoracic (≥25°) or lumbar (\>15°) flexion during standing and walking, which completely disappears in the supine position.

Exclusion criteria

* Severe dyskinesia or on-off fluctuations * Change in the PD medication in the last 3 months prior to enrollment * History of major spinal surgery or musculoskeletal spinal disorders * Need for assistive devices when rising from a chair or bed * Other neurological, orthopedic, or cardiovascular comorbidities that could affect postural control * Inadequate lip seal.

Design outcomes

Primary

MeasureTime frameDescription
Change in the forward trunk flexion (FTF) angleWeek 0, Week 8, Week 12Forward trunk flexion will be assessed using standardized postural photographs. Images will be taken with a camera mounted on a tripod positioned 1 meter above the ground and 3 meters from the participant. The participant will stand in tight-fitting clothing at a predefined location in front of a white wall with a calibration pattern. All camera parameters will remain unchanged throughout the study. Photographs will be analyzed using a semi-automated method, and the extent of forward trunk flexion will be classified according to standardized guidelines for axial postural abnormalities in Parkinson's disease.

Secondary

MeasureTime frameDescription
Mini-Balance Evaluation Systems Test (Mini-BESTest)Week 0, week 4, week 8, week 12The Mini-BESTest is a comprehensive clinical tool designed to assess balance and postural control. The test consists of 14 tasks, comprising a total of 28 items, each rated from 0 to 2, where 0 indicates severe impairment, 1 indicates moderate impairment and 2 stands for normal performance.
Pain Intensity - Numeric Rating ScaleWeek 0, week 4, week 8, week 12Self-reported pain intensity on an 11-point scale (0 = no pain, 10 = worst imaginable pain).
The Parkinson's Disease Questionnaire (PDQ-39)Week 0, week 4, week 8, week 12The 8-item questionnaire assesses quality of life in people with PD. The minimum score is 0, while the maximum is 100. A higher score indicates a lower quality of life.
MDS-Unified Parkinson's Disease Rating Scale: Part II. and III.Week 0, week 4, week 8, week 12This portion of the scale assesses the motor signs of Parkinson´s disease.The maximum total UPDRS score is 272, indicating the worst possible disability from Parkinson's Disease. The minimum total score is 0, indicating no disability from PD. Improvement greater than (-4.9) points or worsening more than (+4.2) points on MDS-UPDRS II+III represent a minimal clinically important difference.
Forced expiratory volume (FEV1)Week 0, week 4, week 8, week 12.Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.
Forced vital capacity (FVC)Week 0, week 4, week 8, week 12.Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.
Peak expiratory flow (PEF)Week 0, week 4, week 8, week 12.Assessments will be performed in accordance with American Thoracic Society/European Thoracic Society guidelines.
Number of Falls in the Previous MonthWeek 0, week 4, week 8, week 12Self-reported number of falls experienced in the preceding month.

Countries

Czechia

Contacts

Primary ContactKateřina Dvořáková, MSc.
katerina.dvorakova@vfn.cz+420 224 965 513
Backup ContactMartin Srp, PhD.
+420 224 965 513

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026